FI974173A - Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan - Google Patents

Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan Download PDF

Info

Publication number
FI974173A
FI974173A FI974173A FI974173A FI974173A FI 974173 A FI974173 A FI 974173A FI 974173 A FI974173 A FI 974173A FI 974173 A FI974173 A FI 974173A FI 974173 A FI974173 A FI 974173A
Authority
FI
Finland
Prior art keywords
endothelin
fragility
glaucoma
arterial
hypertension
Prior art date
Application number
FI974173A
Other languages
English (en)
Swedish (sv)
Other versions
FI974173A0 (fi
Inventor
Kristof Chwalisz
Robert E Garfield
Original Assignee
Kristof Chwalisz
Robert E Garfield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kristof Chwalisz, Robert E Garfield filed Critical Kristof Chwalisz
Publication of FI974173A0 publication Critical patent/FI974173A0/fi
Publication of FI974173A publication Critical patent/FI974173A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
FI974173A 1995-05-08 1997-11-07 Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan FI974173A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/437,462 US5811416A (en) 1994-06-06 1995-05-08 Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
PCT/US1995/015220 WO1996035453A2 (en) 1995-05-08 1995-11-30 Endothelin antagonists and endothelin synthase inhibitors for the prevention and treatment of interine contractility disorders, preeclampsia, atherosclerotic vascular disease, hypertension and or hormone replacement therapy

Publications (2)

Publication Number Publication Date
FI974173A0 FI974173A0 (fi) 1997-11-07
FI974173A true FI974173A (fi) 1998-01-07

Family

ID=23736556

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974173A FI974173A (fi) 1995-05-08 1997-11-07 Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan

Country Status (7)

Country Link
US (1) US5811416A (fi)
EP (1) EP0844884A2 (fi)
AU (1) AU4243396A (fi)
CA (1) CA2220677A1 (fi)
FI (1) FI974173A (fi)
NO (1) NO975128L (fi)
WO (1) WO1996035453A2 (fi)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210918B1 (en) * 1992-10-09 2001-04-03 The Regents Of The University Of California Non-invasive method for detection, diagnosis or prediction of term or pre-term labor
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US6620590B2 (en) 1996-07-11 2003-09-16 Isis Innovation Limited Diagnosis of pre-eclampsia
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
WO2000007578A2 (de) * 1998-08-06 2000-02-17 Vascular Biotech Gmbh Wirkstoffkombination insbesondere zur prophylaxe und therapie von ischämischen organschäden und reperfusionssyndromen
JP2002539257A (ja) * 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6642055B1 (en) 2000-03-31 2003-11-04 Arbogast Pharmaceuticals, Inc. Method for the prediction of preeclampsia and other diseases
WO2002062391A2 (en) * 2001-02-02 2002-08-15 Pharmacia Corporation Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
AUPR516901A0 (en) 2001-05-22 2001-06-14 Occupational & Medical Innovations Ltd Improvements to a single use syringe
ATE493126T1 (de) 2001-11-01 2011-01-15 Spectrum Pharmaceuticals Inc Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
US20070185188A1 (en) * 2006-02-09 2007-08-09 Dorla Mirejovsky Bladder cancer treatment and methods
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
KR20050083827A (ko) * 2002-10-24 2005-08-26 이노스 파마슈티칼스, 인코포레이티드 서방성 ｌ-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
WO2004037235A2 (en) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors
US8026216B2 (en) * 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0308967D0 (en) * 2003-04-17 2003-05-28 Univ London Screen for pre-eclampsia
PT1624878E (pt) * 2003-05-22 2007-01-31 Pantarhei Bioscience Bv Utilização de composições que compreendem um componente estrogénico para o tratamento e prevenção da dor musculoesquelética
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
JP2007521324A (ja) * 2003-09-29 2007-08-02 エノス ファーマシューティカルズ， インク． 徐放性ｌ−アルギニン調合物並びにその製造法及び使用法
WO2007012006A1 (en) * 2005-07-19 2007-01-25 The Population Council, Inc. Methods and compositions for emergency contraception using endothelin receptor antagonists
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
WO2008027839A1 (en) * 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
NZ602909A (en) 2010-04-15 2015-01-30 Marinepolymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20190307107A1 (en) * 2016-06-13 2019-10-10 The Board Of Regents Of The University Of Texas System Compositions and methods for modeling heart failure with preserved ejection fraction
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260276A (en) * 1991-06-14 1993-11-09 Warner-Lambert Company Linear and monocyclic endothelin antagonists
GB9123967D0 (en) * 1991-11-12 1992-01-02 Fujisawa Pharmaceutical Co New compound and its preparation
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
WO1993025580A1 (en) * 1992-06-18 1993-12-23 Immunopharmaceutics, Inc. Cyclic peptides that modulate endothelin activity
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
US5895783A (en) * 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
HUT74465A (en) * 1993-11-16 1996-12-30 Schering Ag Pharmaceutical composition which useable for treatment of uterine contractility disorders containing a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor

Also Published As

Publication number Publication date
WO1996035453A3 (en) 1997-03-13
AU4243396A (en) 1996-11-29
EP0844884A2 (en) 1998-06-03
WO1996035453A2 (en) 1996-11-14
FI974173A0 (fi) 1997-11-07
NO975128D0 (no) 1997-11-07
NO975128L (no) 1998-01-07
CA2220677A1 (en) 1996-11-14
US5811416A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
FI974173A (fi) Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan
US5919813C1 (en) Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
FR2626760B1 (fr) Endoscope, notamment pour la chirurgie endonasale
DE69631473D1 (de) Weichgewebeverankerung
IS5405A (is) Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir
NO862528D0 (no) Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon.
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
ZA989667B (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other MMP-mediated disorders.
NO994481D0 (no) Sammensetninger og fremgangsmÕter for redusering av okulær hypertensjon
BR9708980A (pt) Aperfeiçoamento das taxas de implantação após fertilização invitro
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
IL134394A0 (en) 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
AU2561195A (en) Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
ITSV970008V0 (it) Apparecchio ortodontico per l'espansione e la contrazione ortodontica e ortopedica del mascellare superiore.
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
WO1998020880A3 (en) 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension
FR2767677B1 (fr) Microkeratome pour chirurgie optalmologique
DE69735785D1 (de) Medikament zum Verstopfen von Blutgefässen des Augenhintergrundes
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
DE3578584D1 (de) Therapeutische und vorbeugende ophthalmische loesung fuer intraokulaere hypertension und glaukoma.
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
DZ2438A1 (fr) Atropisomères de 3-hétéroaryl-4(3h)-quinazolinones.
WO1999057133A3 (en) Inhibitors of nf-kb activation
FR2570266B1 (fr) Dispositif ecarteur, notamment pour la chirurgie du rachis
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques